David Raben Sells 5,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) insider David Raben sold 5,500 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $22.88, for a total transaction of $125,840.00. Following the sale, the insider owned 55,286 shares of the company’s stock, valued at approximately $1,264,943.68. The trade was a 9.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Raben also recently made the following trade(s):

• On Tuesday, March 3rd, David Raben sold 200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.45, for a total transaction of $3,690.00.
• On Wednesday, March 4th, David Raben sold 16,300 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.52, for a total transaction of $301,876.00.

Bicara Therapeutics Stock Down 2.9%

NASDAQ BCAX opened at $21.28 on Thursday. The company has a 50-day simple moving average of $19.96 and a two-hundred day simple moving average of $17.87. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $24.25. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -8.41 and a beta of -1.23.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.04. Equities analysts expect that Bicara Therapeutics Inc. will post -2.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its stake in shares of Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after acquiring an additional 4,585 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after buying an additional 2,771,868 shares during the period. Invesco Ltd. increased its position in shares of Bicara Therapeutics by 20.6% during the fourth quarter. Invesco Ltd. now owns 21,006 shares of the company’s stock valued at $354,000 after buying an additional 3,595 shares during the period. VARCOV Co. purchased a new position in shares of Bicara Therapeutics during the fourth quarter valued at about $263,000. Finally, Virtus Investment Advisers LLC increased its position in shares of Bicara Therapeutics by 46.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 14,395 shares of the company’s stock valued at $242,000 after buying an additional 4,560 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Citigroup assumed coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set an “outperform” rating for the company. Wells Fargo & Company upped their price objective on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Finally, Bank of America assumed coverage on shares of Bicara Therapeutics in a research note on Wednesday, March 25th. They set a “buy” rating and a $35.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $28.00.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.